LEBLANC, MADELINE ROSE
 Distribuzione geografica
Continente #
NA - Nord America 53
EU - Europa 49
AS - Asia 36
AF - Africa 2
Totale 140
Nazione #
US - Stati Uniti d'America 53
SG - Singapore 15
DE - Germania 14
IT - Italia 14
CN - Cina 13
GB - Regno Unito 7
SE - Svezia 7
IN - India 5
FR - Francia 3
IE - Irlanda 3
JO - Giordania 2
TG - Togo 2
PH - Filippine 1
RU - Federazione Russa 1
Totale 140
Città #
Singapore 14
Chandler 9
Comano 8
Santa Clara 8
Southend 6
Frankfurt am Main 5
Princeton 4
Dublin 3
Redwood City 3
Amman 2
Berlin 2
Boardman 2
Bologna 2
Des Moines 2
Houston 2
Jinan 2
Lohne 2
Lomé 2
Nanjing 2
Naples 2
Redmond 2
Shenyang 2
Turin 2
Westminster 2
Bengaluru 1
Changsha 1
Jinhua 1
London 1
Los Angeles 1
Nanchang 1
Ningbo 1
Norwalk 1
Parsippany 1
Seattle 1
Taiyuan 1
Wilmington 1
Zhengzhou 1
Totale 103
Nome #
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial 80
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial 64
Totale 144
Categoria #
all - tutte 555
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 555


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202020 0 0 0 0 0 0 0 4 3 11 2 0
2020/202123 4 0 0 0 0 9 2 0 0 0 4 4
2021/202215 0 0 2 0 4 0 0 2 0 0 3 4
2022/202343 7 8 3 2 4 4 0 3 8 0 4 0
2023/20249 1 6 1 0 0 0 0 0 0 0 0 1
2024/202534 4 11 0 4 12 3 0 0 0 0 0 0
Totale 144